- Conditions
- Amyloidosis, Hereditary Transthyretin-Mediated Amyloid Polyneuropathy, Metabolic Diseases, +6 more
- Locations
-
- Mayo Clinic - Arizona Scottsdale, Arizona, United States
- Mayo Clinic - Jacksonville Jacksonville, Florida, United States
- Indiana University School of Medicine - Indianapolis Indianapolis, Indiana, United States
- University of Kansas Medical Center Kansas City, Kansas, United States
Clinical trial condition
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Explore clinical trials studying Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Study availability and eligibility vary by location and protocol.
2 public trials
0 recruiting studies
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy trial results
Active, Not Recruiting
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NCT05071300
- Conditions
- Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
- Locations
-
- Mayo Clinic Scottsdale, Arizona, United States
- Indiana University Health University Hospital Indianapolis, Indiana, United States
- Johns Hopkins University Neurology Research Office Baltimore, Maryland, United States
- Boston University School of Medicine Boston, Massachusetts, United States